Project Grant HT94252410017

This $249,645 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The Children's Hospital Corporation (Boston Children's Hospital) aims to develop a novel immunotherapy strategy using gene-edited, tumor-specific B cells. The goal is to leverage the tumor-suppressing and immune-stimulating functions of these engineered B cells to enhance anti-cancer immunity. The project will exploit an optimized B cell gene editing protocol to redirect the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The $399,669 grant, awarded on September 3, 2024, will support the development of an autologous ATCT that targets multiple GBM-specific antigens unique to each patient. The key innovation is the use of Prussian...

This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $709,554 to Emory University to advance the understanding of how a novel neoadjuvant therapy, combining the antibody pepinemab (which blocks SEMA4D signaling) with immune checkpoint blockade, impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The key objectives are to: 1) gain insight into how blocking SEMA4D impacts...

This federal Project Grant award of $641,336 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to develop an innovative immunotherapy approach for non-small cell lung cancer (NSCLC) treatment. The research will target the GARP-TGF-beta axis, which can drive immune dysfunction and resistance to immune checkpoint blockade therapies in NSCLC. The awarded project, conducted by The Ohio State University, will define how GARP inhibits CD8+ T cell...

This $481,818 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the efficacy of CD19-directed chimeric antigen receptor T cell (CAR-T) therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), particularly in cases with TP53 mutations associated with chemotherapy resistance. The research seeks to evaluate the potential of inhibiting free fatty acid (FFA) uptake, via genetic and pharmacological targeting of the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Weill Medical College of Cornell University provides $237,724.00 in funding from March 12, 2025 to February 28, 2027 to investigate the role of p53 mutational status as a key determinant of radiation therapy's ability to induce cancer cell-intrinsic interferon-I pathway activation and in situ immunization. The research will utilize various p53-isogenic mouse and human cancer cell lines as...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $194,013.00 to the University of Southern California to develop a new monoclonal antibody therapy targeting isoaspartylated ELAVL4 protein for the treatment of small cell lung cancer (SCLC). The key objectives are to: 1) Generate a mouse monoclonal antibody specifically binding to the isoaspartylated form of the ELAVL4 protein, which is expressed on the surface of SCLC tumors...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $560,458 to Childrens Mercy Hospital in Kansas City, Missouri to develop a strategy and novel compounds that efficiently induce cell death specifically in cancer cells deficient in the p53 tumor suppressor gene. The research aims to determine how simultaneously inducing reactive oxygen species (ROS)-mediated DNA double-strand breaks and inhibiting the DNA damage response...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a "next-generation" precision adoptive T cell therapy approach for the treatment of pediatric high-grade gliomas. The $474,656 award, which runs from August 2024 to July 2029, will enable the University of Florida to: 1) evaluate the safety, efficacy, and immunologic effects of this precision ACT targeting neoantigens and tumor-associated antigens in...

The National Cancer Institute awarded a 5-year, $483,041 Project Grant (CFDA 93.396 - Cancer Biology Research) to Baylor College of Medicine in Houston, TX to engineer transcription factors that can improve the persistence and effector function of therapeutic T cells for cancer immunotherapy. The goals are to: 1) understand the molecular mechanisms regulating T cell exhaustion, 2) increase resistance to T cell dysfunction through multiplexed transcription factor perturbations, and 3) determine...